In short
This article explores the use of Lapatinib, a targeted cancer drug, in various clinical trials. Lapatinib is being studied for its effectiveness in treating different types of cancer, particularly breast cancer. The trials aim to evaluate the drug's efficacy, safety, and its ability to penetrate tumors and the brain. Understanding these trials can provide valuable insights into potential new treatment options for cancer patients.
At a glance
- Drug Name
- Lapatinib (also known as GW572016, Tykerb, Tyverb)
- Main Cancer Types Studied
- Breast cancer, endometrial cancer, head and neck cancer, vestibular schwannomas
- Mechanism of Action
- Dual inhibitor of HER1 and HER2 tyrosine kinases
- Administration
- Oral, typically once daily
- Dosage Range
- 500 mg to 1500 mg daily, varying by trial
- Key Objectives
- Assess efficacy, safety, tumor penetration, brain penetration, survival impact
- Combination Therapies
- Tested with capecitabine in some trials
- Special Investigations
- Brain and tumor penetration studies using PET scans
What is LAPATINIB?
LAPATINIB is a medication used in the treatment of certain types of breast cancer. It's also known by other names such as Tykerb, Tyverb, and GW572016. LAPATINIB is a type of drug called a tyrosine kinase inhibitor, which means it works by blocking specific proteins that are involved in cancer growth.
How LAPATINIB Works
LAPATINIB targets two specific proteins called HER1 (also known as EGFR) and HER2. These proteins are often found in higher amounts on the surface of some cancer cells, especially in certain types of breast cancer. By blocking these proteins, LAPATINIB can help to slow down or stop the growth of cancer cells.
The drug works inside the cancer cells to interrupt the signaling pathways that promote cell growth and survival. This can lead to the death of cancer cells and shrinkage of tumors.
Conditions Treated with LAPATINIB
LAPATINIB is primarily used to treat certain types of breast cancer. Specifically, it's used for:
- HER2-positive metastatic breast cancer: This is breast cancer that has spread to other parts of the body and has high levels of the HER2 protein.
- Advanced or metastatic breast cancer: In patients who have already been treated with other therapies.
- Hormone receptor-positive metastatic breast cancer: In postmenopausal women, when used in combination with an aromatase inhibitor.
In some clinical trials, LAPATINIB has also been studied for use in other types of cancer, such as bladder cancer.
Dosage and Administration
LAPATINIB is taken orally in tablet form. The dosage can vary depending on the specific condition being treated and whether it's being used alone or in combination with other drugs. Some common dosages include:
- 1250 mg (5 tablets) taken once daily when used with capecitabine.
- 1500 mg taken once daily when used alone.
It's important to take LAPATINIB exactly as prescribed by your doctor. The medication should be taken at least one hour before or one hour after a meal.
Clinical Studies and Efficacy
Several clinical studies have been conducted to evaluate the effectiveness of LAPATINIB:
- In a study of patients with HER2-positive metastatic breast cancer, LAPATINIB combined with capecitabine showed improved progression-free survival compared to capecitabine alone.
- Another study looked at LAPATINIB as a neoadjuvant therapy (treatment given before the main treatment) in patients with locally advanced HER2-positive breast cancer. After 6 weeks of treatment, some patients showed tumor shrinkage.
Side Effects and Safety
Like all medications, LAPATINIB can cause side effects. Common side effects may include:
- Diarrhea
- Nausea
- Rash
- Fatigue
- Loss of appetite
More serious side effects can occur, including liver problems and heart problems. Your doctor will monitor you closely for these potential side effects.
Combination Therapies
LAPATINIB is often used in combination with other cancer treatments. Some common combinations include:
- LAPATINIB with capecitabine (Xeloda): This combination is used in patients with advanced or metastatic HER2-positive breast cancer.
- LAPATINIB with letrozole: This combination is used in postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.
- LAPATINIB with trastuzumab (Herceptin): This combination has been studied in clinical trials for patients with HER2-positive breast cancer.
These combinations may offer improved efficacy compared to single-drug treatments in certain patient populations.